Is homocysteine a relevant cardiovascular risk factor?
- 19 Downloads
Scientific research is searching constantly for new markers to help stage the progress and prognosis of cardiovascular disease. Over the past few decades, homocysteine has been suggested as a risk factor involved in the promotion of atherosclerosis and thrombotic vascular events. Several large observational studies have indicated a relationship between homocysteine and cardiovascular illness. However, more robust prospective trials reveal a weaker association between the two than do case-control and cross-sectional data. Recently, many randomized controlled trials have evaluated the impact of homocysteine-lowering therapy on vascular risk. The overall evidence suggests a null effect, thereby failing to validate the hypothesis that a reduction in homocysteine levels would result in clinical benefit. This review outlines the latest relevant data and illustrates why the use of homocysteine as a screening tool or a target of cardiovascular treatment cannot be recommended.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 8.Mudd SH, Levy HL, Skovby F: Disorders of transsulfuration. In The Metabolic and Molecular Basis of Inherited Disease, vol 1, edn 7. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 1995:1279–1327.Google Scholar
- 11.Homocysteine Lowering Trialists’ Collaboration: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998, 316:894–898.Google Scholar
- 39.Righetti M, Ferrario GM, Milani S, et al.: Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 2003, 9:9PI19–9PI24.Google Scholar
- 40.Baker F, Picton D, Blackwood S, et al.: Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation 2002, 106(Suppl 2):741S.Google Scholar
- 43.Albert C: A randomized trial of folic acid and B-vitamins in the secondary prevention of cardiovascular events in women: Results from the Women’s Antioxidant and Folic Acid Cardiovascular Study (WAFACS). Presented at the American Heart Association 2006 Scientific Sessions. Chicago; November 13, 2006.Google Scholar
- 44.Ebbing M: Results from the Western Norway B-Vitamin Intervention Trial (WENBIT). Presented at the European Society of Cardiology 2007 World Congress. Vienna; September 4, 2007.Google Scholar
- 46.Vogel JHK, Bolling SF, Costello RB, et al.: Integrating complementary medicine into cardiovascular medicine. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine). J Am Coll Cardiol 2005, 46:184–221.PubMedCrossRefGoogle Scholar